风湿科需慎重选择非甾体类抗炎药

[1] Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review[J] . Alaa Rostom,Katherine Muir,Catherine Dubé,Emilie Jolicoeur,Michel Boucher,Janet Joyce,Peter Tugwell,George W. Wells.Clinical Gastroenterology and Hepatology . 2007 (7)

[2] Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term （MEDAL） programme: a randomised comparison[J] . Loren Laine,Sean P Curtis,Byron Cryer,Amarjot Kaur,Christopher P Cannon.The Lancet . 2007 (9560)

[3] Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study[J] . Gurkirpal Singh,John G. Fort,Jay L. Goldstein,Roger A. Levy,Patrick S. Hanrahan,Alfonso E. Bello,Lilia Andrade-Ortega,Carl Wallemark,Naurang M. Agrawal,Glenn M. Eisen,William F. Stenson,George Triadafilopoulos.The American Journal of Medicine . 2006 (3)

[4] Prevention of anti‐inflammatory drug‐induced gastrointestinal damage: Benefits and risks of therapeutic strategies[J] . Angel Lanas,Richard Hunt.Annals of Medicine . 2006 (6)

[5] Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use [J]. GASTROENTEROLOGY, 2003, 124 (02) : 288 - 292

[6] Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications[J] . Andrew Whelton.The American Journal of Medicine . 1999 (5)

[7] British society for rheumatology and British health professionals in rheumatolagy guideline for the management of rheumatoid arthritis（the first twa years）. Luqmani R,Hennell S,Estraeh C, et al. Rheumatology . 2006

[8] Microbial flora in NSAID-induced intestinal damage:a role for antibiotics?. Lanas A,Scarpignato C. Digestion . 2006

[1] Gastrointestinal Safety of Cyclooxygenase-2 Inhibitors: A Cochrane Collaboration Systematic Review[J] . Alaa Rostom,Katherine Muir,Catherine Dubé,Emilie Jolicoeur,Michel Boucher,Janet Joyce,Peter Tugwell,George W. Wells.Clinical Gastroenterology and Hepatology . 2007 (7)

[2] Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term （MEDAL） programme: a randomised comparison[J] . Loren Laine,Sean P Curtis,Byron Cryer,Amarjot Kaur,Christopher P Cannon.The Lancet . 2007 (9560)

[3] Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study[J] . Gurkirpal Singh,John G. Fort,Jay L. Goldstein,Roger A. Levy,Patrick S. Hanrahan,Alfonso E. Bello,Lilia Andrade-Ortega,Carl Wallemark,Naurang M. Agrawal,Glenn M. Eisen,William F. Stenson,George Triadafilopoulos.The American Journal of Medicine . 2006 (3)

[4] Prevention of anti‐inflammatory drug‐induced gastrointestinal damage: Benefits and risks of therapeutic strategies[J] . Angel Lanas,Richard Hunt.Annals of Medicine . 2006 (6)

[5] Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use [J]. GASTROENTEROLOGY, 2003, 124 (02) : 288 - 292

[6] Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications[J] . Andrew Whelton.The American Journal of Medicine . 1999 (5)

[7] British society for rheumatology and British health professionals in rheumatolagy guideline for the management of rheumatoid arthritis（the first twa years）. Luqmani R,Hennell S,Estraeh C, et al. Rheumatology . 2006

[8] Microbial flora in NSAID-induced intestinal damage:a role for antibiotics?. Lanas A,Scarpignato C. Digestion . 2006